Agenus Inc. vs. Krystal Biotech, Inc. Common Stock
Krystal Biotech, Inc. Common Stock (KRYS) comes out ahead, leading on 5 of 9 compared factors.
Size & Scale
| AGEN | KRYS | |
|---|---|---|
| Market Cap | $334.50 million | $10.40 billion |
| Revenue (TTM) | $132.69 million | $440.48 million |
| Net Income (TTM) | $91.94 million | $241.47 million |
KRYS leads on 3 of 3 size & scale factors.
Valuation
| AGEN | KRYS | |
|---|---|---|
| P/E Ratio | 2.88 | 43.08 |
| Price / Book | -1.62 | 7.65 |
| Price / Sales | 2.52 | 23.60 |
AGEN leads on 3 of 3 valuation factors.
Profitability
| AGEN | KRYS | |
|---|---|---|
| Net Margin | 69.29% | 54.82% |
| Return on Equity | -44.66% | 17.77% |
AGEN and KRYS split the profitability factors evenly.
Risk & Sentiment
| AGEN | KRYS | |
|---|---|---|
| Short Interest | 22.67% | 0.11% |
KRYS leads on 1 of 1 risk & sentiment factors.
Dig deeper: AGEN overview, AGEN financials, KRYS overview, KRYS financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.